Premium
Normal midtrimester (17‐20 weeks) genetic sonogram decreases amniocentesis rate in a high‐risk population.
Author(s) -
Pinette M G,
Garrett J,
Salvo A,
Blackstone J,
Pinette S G,
Boutin N,
Cartin A
Publication year - 2001
Publication title -
journal of ultrasound in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.574
H-Index - 91
eISSN - 1550-9613
pISSN - 0278-4297
DOI - 10.7863/jum.2001.20.6.639
Subject(s) - medicine , amniocentesis , triple test , aneuploidy , advanced maternal age , trisomy , obstetrics , population , gynecology , pregnancy , prenatal diagnosis , fetus , chromosome , genetics , environmental health , gene , biology
To evaluate a screening protocol using advanced maternal age, triple‐marker screening, and genetic sonography. We compared adverse chromosomal outcomes of pregnancy in 1556 women referred for increased risk of aneuploidy because of either advanced maternal age or triple‐marker test results. Patients were counseled about the results of the triple‐marker test and subsequent sonography, which led to a patient decision of whether to pursue amniocentesis. Fetal measurements and structural abnormalities were compared with chromosomal findings. When patients elected amniocentesis, karyotypes were obtained. Genetic sonography reduced the rate of amniocentesis by 61% overall and by 40% when compared with an alpha‐fetoprotein profile alone. The sensitivity of sonography combined with the triple‐marker screen for the detection of trisomy 21 was 87% compared with 91% for the triple‐marker screen alone. This study confirmed that sonographic findings in a targeted population, in combination with other risk markers (advanced maternal age and triple‐marker screening), can be used to assess the risk of aneuploidy. Biometry provides additional information for assessing the risk of aneuploidy. Combining advanced maternal age, serum triple‐marker screening, and sonographic screening may provide better risk prediction for use in clinical counseling.